Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan

References

• Ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL-23/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):1. doi: 10.1111/sji.12946.
   Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J Clin Med. 2023;12(5):1934. doi: 10.3390/jcm12051934.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Conrad C. TYK-ing all the boxes in psoriasis. J Allergy Clin Immunol. 2022;149(6):1936–7. doi: 10.1016/j.jaci.2022.03.014.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. doi: 10.1016/j.jaad.2022.07.002.
   PubMed Web of Science ®Google Scholar
• Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi: 10.1016/j.jaad.2022.08.061.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Tada Y, Hippeli L, et al. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol. 2023;50(5):588–595. doi: 10.1111/1346-8138.16740.
   PubMed Web of Science ®Google Scholar
• Najar Nobari N, Shahidi Dadras M, Nasiri S, et al. Neutrophil/platelet to lymphocyte ratio in monitoring of response to TNF-α inhibitors in psoriatic patients. Dermatol Ther. 2020;33(4):e13457.
   PubMed Web of Science ®Google Scholar
• Sen BB, Rifaioglu EN, Ekiz O, et al. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2014;33(3):223–227. doi: 10.3109/15569527.2013.834498.
   PubMed Web of Science ®Google Scholar
• Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(6):700–711. doi: 10.1111/jdv.12257.
   PubMed Web of Science ®Google Scholar
• Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43(3):305–310. doi: 10.1111/1346-8138.13061.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. Biomarkers and predictive factors for treatment response to tumor necrosis factor-α inhibitors in patients with psoriasis. J Clin Med. 2023;12(3):974. doi: 10.3390/jcm12030974.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The eosinophil-to-lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis. J Clin Med. 2023;12(6):2201. doi: 10.3390/jcm12062201.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32(8):1305–1313. doi: 10.1111/jdv.14913.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Strober B, Gordon KB, et al., editors. Abstract No.:2127—deucravacitinib improves psoriasis symptoms and signs diary domain scores in patients with moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 and POETYK PSO-2 studies. EADV 30th Congress; 2021 Sep 29–Oct 2; virtual; 2021.
   Google Scholar
• Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol. 2018;138(6):1311–1317. doi: 10.1016/j.jid.2017.12.029.
   PubMed Web of Science ®Google Scholar
• Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol. 2011;165(2):277–284. doi: 10.1111/j.1365-2133.2011.10347.x.
   PubMed Web of Science ®Google Scholar
• Ayasse MT, Buddenkotte J, Alam M, et al. Role of neuroimmune circuits and pruritus in psoriasis. Exp Dermatol. 2020;29(4):414–426. doi: 10.1111/exd.14071.
   PubMed Web of Science ®Google Scholar
• Tseng PY, Hoon MA. Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med. 2021;13(619):eabe3037. doi: 10.1126/scitranslmed.abe3037.
   PubMed Web of Science ®Google Scholar
• Burfoot MS, Rogers NC, Watling D, et al. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. J Biol Chem. 1997;272(39):24183–24190. doi: 10.1074/jbc.272.39.24183.
   PubMed Web of Science ®Google Scholar
• Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973–8995. doi: 10.1021/acs.jmedchem.9b00444.
   PubMed Web of Science ®Google Scholar
• He X, Chen X, Zhang H, et al. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opin Ther Pat. 2019;29(2):137–149. doi: 10.1080/13543776.2019.1567713.
   PubMed Web of Science ®Google Scholar
• Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–352. doi: 10.1007/s40265-020-01261-8.
   PubMed Web of Science ®Google Scholar
• Catlett IM, Hu Y, Gao L, et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010–2020.e8. doi: 10.1016/j.jaci.2021.11.001.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869–879. doi: 10.1111/1346-8138.16763.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib. J Dermatol. 2023;50(10):1301–1312. doi: 10.1111/1346-8138.16879.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi: 10.1111/1346-8138.16549.
   PubMed Web of Science ®Google Scholar
• Hagino THR, Yoshida M, Fujimoto E, et al. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:3201–3212. doi: 10.2147/CCID.S439053.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/science.abd4570.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yin M, Jia H, et al. ISG20 stimulates anti-tumor immunity via a double-stranded RNA-induced interferon response in ovarian cancer. Front Immunol. 2023;14:1176103. doi: 10.3389/fimmu.2023.1176103.
   PubMed Web of Science ®Google Scholar